A Phase 1b Study of Lenvatinib plus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma: Extended Analysis of Study 116

By sjmartinez • August 8, 2024

Kudo M, Finn RS, Ikeda M, Sung MW, Baron AD, Okusaka T, Kobayashi M, Kumada H, Kaneko S, Pracht M, Meyer T, Nagao S, Saito K, Mody K, Ramji Z, Dubrovsky L, Llovet JM. A Phase 1b Study of Lenvatinib plus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma: Extended Analysis of Study 116. Liver Cancer. 2023 Nov 13;13(4):451-458. doi: 10.1159/000535154. PMID: 39114764; PMCID: PMC11305660.

Tags: Hematology/Oncology, Hepatocellular carcinoma, lenvatinib, overall survival, pembrolizumab, Progression-free survival, Publications

Early-Onset Gastric Cancer as a High-Risk Disease Entity in the United States: Clinicopathologic Features, Regional Variation, and Outcomes

Castillo DR, Shah P, Tai D, Guo M, Hazeltine M, Guzman S, Park D, Mannan R, Xing Y, Brar G, Raoof M, Eng C, Wu[...]

Women and Herpes Zoster in the United States: Risk and Prevention Management-A Narrative Review

Campos R, Caldera F, Carrico J, Cochrane C, Eltoukhy N, Huang C, Kneller S, Rutland C, Slovis J. Women and Herpes Zoster in the United[...]

Newly Diagnosed VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome in a Patient Presenting With Legionella Pneumonia

Sanchez Jimenez A, Hirt C, Anand S, Tsai S, Ma J. Newly Diagnosed VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome in a Patient Presenting[...]